EMEA-001830-PIP01-15-M02
Key facts
Invented name |
|
Active substance |
Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
|
Therapeutic area |
Vaccines
|
Decision number |
P/0188/2020
|
PIP number |
EMEA-001830-PIP01-15-M02
|
Pharmaceutical form(s) |
Suspension for injection
|
Condition(s) / indication(s) |
Prevention of influenza infection
|
Route(s) of administration |
Intramuscular use
|
Contact for public enquiries |
Seqirus S.r.l.
Tel. +39 0577096405; +39 0577096401 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-001830-PIP01-15-M02
|
Compliance opinion date |
16/12/2022
|
Compliance outcome |
positive
|